Business Wire

LabVantage Solutions and The Netherlands Forensic Institute (NFI) Partner to Advance Digital Transformation in Forensic Science

4.12.2024 13:30:00 CET | Business Wire | Press release

Share

—New Collaboration Enhances NFI’s IT Infrastructure with Advanced LIMS to Streamline Workflows, Improve Data Integrity, and Optimize Forensic Operations—

LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS platforms enabling rapid deployment at reduced costs, and The Netherlands Forensic Institute (NFI) today jointly announced a partnership to digitalize forensic laboratory workflows as part of NFI’s IT renewal initiative. A key aspect of this collaboration is the implementation of LabVantage Solutions’ Laboratory Information Management System (LIMS), which is designed to streamline NFI’s forensic operations by replacing fragmented processes and incorporating advanced capabilities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204274659/en/

null

(Graphic: Business Wire)

NFI’s IT renewal initiative aims to modernize its infrastructure by replacing outdated manual systems with streamlined, automated workflows. Currently, the workflows involve multiple manual registrations across different systems, which can lead to time-consuming tasks and potential inconsistencies. The integration of LabVantage LIMS will unify data entry and enhance traceability, ensuring that data is efficiently recorded and utilized. It will also improve overall clarity and operational efficiency across forensic investigations, saving valuable time for all involved.

Peter Blom, Chief Information Officer of NFI, expressed his enthusiasm for the project: “This partnership marks a significant milestone in our journey to innovate and improve our forensic services. By integrating a sophisticated LIMS, we are setting a new standard in forensic science.”

“We are proud to work alongside NFI in their mission to enhance forensic operations,” said Michel Gerlicher, President, LabVantage International. “This collaboration will bring about a new era of efficiency and reliability in their laboratory workflows.”

The project includes contributions from Protinus, which served as the IT broker, and Capgemini, which is developing the sovereign cloud infrastructure to host the LIMS. The new system will integrate seamlessly into NFI’s operations, ensuring compliance with stringent security standards while enabling forensic experts to work faster and more confidently. By leveraging a secure, sovereign cloud infrastructure, the partnership will meet the highest standards of data protection and regulatory compliance, including BIO (Baseline Information Security for Government) and BBN (Baseline Information Security for Enterprises) requirements.

Alan Marcus, Chief Growth Officer at LabVantage Solutions, emphasized the broader implications of this alliance: “We are excited to see the real-life impact our investments in industry-specific solutions bring to our clients. With Software-as-a-Service (SaaS) becoming the de facto delivery standard, we expect vertical solutions to prove increasingly impactful, allowing clients to benefit from the latest innovations without being held back by past adaptations required by industry-agnostic software. NFI’s validation that our forensics solutions are fit for purpose is encouraging, and we are humbled to contribute to the fact-finding mission of NFI’s world-leading forensic laboratories.”

LabVantage Solutions, in joint effort with Protinus and Capgemini, will ensure the new system is secure and fully compliant with all required standards. By implementing LabVantage LIMS, NFI will streamline processes, enhance data accuracy, and improve data management, reinforcing its commitment to innovation and reliability. This partnership strengthens NFI’s role as a leader in delivering reliable forensic services to organizations around the world, while further establishing LabVantage Solutions’ prominence in the enterprise laboratory software solutions industry.

To learn more about LabVantage Solutions’ end-to-end informatics solutions for the complete forensic life cycle, please visit labvantage.com or contact us here.

About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. Its highly configurable, 100% browser-based platform consists of LIMS, ELN, LES, SDMS, and advanced analytics, supporting seamless deployment into any environment. Serving over 1,500 customers across life sciences, pharmaceuticals, biobanking, food & beverage, forensics, and more, LabVantage Solutions empowers innovation, helps improve product quality, and ensures compliance with industry regulations. Headquartered in Somerset, NJ, with offices worldwide, LabVantage Solutions has driven laboratory digital transformation for over 40 years. For more information, visit labvantage.com.

About The Netherlands Forensic Institute (NFI):
The Netherlands Forensic Institute is dedicated to providing high-quality forensic services to support justice, peace, and security. The NFI has achieved this position by constantly improving its products and services. Science and innovation at the NFI are strongly driven by experiences from forensic practice. Through this innovative approach and commitment to excellence, the NFI serves both national and international clients, offering a wide range of forensic products and services. For more information, visit https://www.forensischinstituut.nl/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241204274659/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye